Novo Nordisk shines at CIIE and deepens its layout in China| Updated: Nov 4, 2022 L M S

Novo Nordisk, a world-leading biomedical enterprise, has exhibited a total of 18 innovative drugs and 10 injection devices at the China International Import Expo, or CIIE, and continued to deepen its layout in China.

"The fifth CIIE is on schedule, showing China's openness, sincerity of cooperation and tolerance, and the resilience and vitality of its economy," said Zhou Xiaping, senior vice president and president of the China region at Novo Noridsk.

As an old friend that has not missed a CIIE for 5 years, Novo Nordisk has accelerated its transformation into an investor, placing funds four times into China to deepen the layout of its whole industrial chain integrating R&D, production and operation.

At this year's Expo, Novo Nordisk will focus on 14 innovative drugs and eight injectable devices in the areas of diabetes, hemophilia and growth disorders, and will also set up the first obesity science area in the exhibition hall.

Zhou added that the importance of China has been elevated to the highest level in Novo Nordisk's global R&D strategy.

Moving forwards, Novo Nordisk will seize the opportunities inherent in China's high-quality development and promote a whole industry chain layout to upgrade again, which expresses their confidence in the Chinese market and long-term commitment to Chinese medical care.


  • Address No 200 Shengang Avenue, Pudong New Area, Shanghai, China
  • Zip Code 201306
  • TEL +86-21-68283063
  • FAX +86-21-68283000